GlassScriptPhysician profile
Lisa M Aenlle
NPI 1497919443
$3,242.29
in general payments reported to CMS, 2019-2025
39 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $226 · 2021: $385 · 2022: $493 · 2023: $424 · 2024: $886 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,147.45 | 2021-2025 | Botox, Ubrelvy |
| Ucb, INC. | $191.25 | 2019-2025 | Fintepla, Zilbrysq |
| Eisai INC. | $182.28 | 2023-2025 | |
| Allergan, INC. | $142.84 | 2019-2021 | |
| Argenx US, INC. | $111.74 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $102.96 | 2021-2024 | Emgality, Amyvid, Reyvow |
| Pfizer INC. | $100.31 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $98.97 | 2019-2023 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $89.63 | 2019-2025 | |
| Lundbeck LLC | $89.54 | 2023-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $80.93 | 2019-2025 | Austedo Xr |
| Celgene Corporation | $74.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.86 | 2022-2023 | Gammagard |
| Amgen INC. | $60.89 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $53.67 | 2022-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Aenlle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.